

July 17, 2025

Nobelpharma Co., Ltd.

Notification of Presentation of "Effective Treatment Results for Trigeminal Neuralgia (TN)" at the 77th Annual Meeting of the American Academy of Neurology (AAN)

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Managing Director and CEO : Jin Shiomura) announced that Dr. Noro presented the results of an Investigator-Initiated study involving the intravenous administration of fosphenytoin sodium hydrate (product name: Fostoin 750mg for Injection) for the treatment of trigeminal neuralgia at the 77th Annual Meeting of the American Academy of Neurology (AAN) held April 5-9, 2025, San Diego, USA.

This study was a randomized controlled trial (RCT) involving patients with refractory trigeminal neuralgia who had been treated with carbamazepine or other oral medications. In the study, patients received either Fostoin or a placebo (injectable saline) in a double-blinded manner. This is the first RCT in this area and is noteworthy.

Principal Investigator



Dr. Shusaku Noro,
Director of Neurosurgery, Nakamura Memorial Hospital

The presentation at AAN has been featured in various medical media worldwide, including Medscape, European Medical Journal, German Neurology Society Media (DGN), and Dutch Neurology Expert Media (TNN).

Fosphenytoin sodium hydrate (product name: Fostoin 750mg for Injection) has been approved in Japan as of May 2025 for the following indications and efficacy:

- Status epilepticus

- Prevention of epileptic seizures associated with neurosurgical procedures or traumatic brain injury
- Temporary alternative therapy for patients with epilepsy receiving oral phenytoin

What is Trigeminal Neuralgia?

The trigeminal nerve transmits sensation from the face to the brain. Trigeminal neuralgia is a condition in which severe, stabbing pain occurs on one side of the face due to compression of the trigeminal nerve by a blood vessel in the brain. It can also occur due to tumors. In some cases, the compression cannot be confirmed by imaging.

Dairy activities such as washing the face, brushing teeth, or eating can trigger pain, which may recur many times a day.

Investigator-Initiated study

An Investigator-Initiated study is a clinical trial planned and conducted by an Investigator.

Our company will continue to contribute to society through the provision of unmet needs drugs and medical devices.

Research Details

JRCT "Japan Registry of Clinical Trials"

<https://jrct.mhlw.go.jp/latest-detail/JRCT2011220043>

Note

The information contained in this press release is intended for members of the press, investors, and journalists. It is not intended to promote or advertise medical products, including those containing pharmaceutical ingredients. This is not an advertisement, nor is it intended to solicit investment.

[Contact Information]

<https://www.nobelpharma.co.jp/en/contact/general-form>

Etsuro Hayashi, Head of Communications

1-17-24 Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800